RxDoctor Payments Data

Ralph Ortiz

Pain Medicine · Freeville, NYNPI 1720171879

Payments from drug & device makers

$5,735in general payments, 2019–2025

Across 295 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$818
  • Si-bone, Inc.$459
  • SPR Therapeutics, Inc$388
  • AbbVie$340
  • Biohaven Pharmaceuticals, Inc.$337
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,735100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,735 in reported general payments places this provider in the 75th percentile of 503 pain medicine providers in New York.

See all pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$126,818
Medicare patients
122
Services billed
3,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl149$95,724
Xtampza ErOxycodone Myristate140$67,497
PercocetOxycodone Hcl/Acetaminophen13$58,878
RelistorMethylnaltrexone Bromide19$48,369
Oxycodone Hcl1,734$40,045
Morphine Sulfate ErMorphine Sulfate278$25,987
MovantikNaloxegol Oxalate59$23,393
Nurtec OdtRimegepant Sulfate13$21,996
Nucynta ErTapentadol Hcl12$17,672
Fentanyl120$15,033
Naloxone Hcl155$11,118
Pregabalin140$7,016
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen228$6,395
SymproicNaldemedine Tosylate12$5,464
Metaxalone20$4,378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er$1,231$85,169152 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$818$48,36919 claims
PfizerNurtec Odt$315$21,99613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 503 pain medicine providers in New York.

Other pain medicine in Freeville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →